Updates in non-small cell lung cancer - Insights from the 2009 45 th annual meeting of the American Society of Clinical Oncology

Journal of Hematology and Oncology

Volumn 3, Issue , 2010, Pages

  Mirshahidi, Hamid R ^a   Hsueh, Chung T ^a  

^a LOMA LINDA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; VANDETANIB; VORINOSTAT; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CYTOPENIA; DIARRHEA; DRUG BIOAVAILABILITY; DRUG ERUPTION; DRUG FATALITY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; FATIGUE; FOLLOW UP; GENE MUTATION; HEMOPTYSIS; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MAINTENANCE THERAPY; MEDICAL SOCIETY; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; QT PROLONGATION; REVIEW; SURVIVAL TIME; THROMBOSIS; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT; LUNG TUMOR; ORGANIZATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CONGRESSES AS TOPIC; HUMANS; LUNG NEOPLASMS;

EID: 77951596820     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-3-18     Document Type: Review

References (44)

1. Pre-operative chemotherapy in patients with resectable non-small cell lung cancer (NSCLC): First results of the MRC LU22/NVALT/EORTC 08012 multi-centre randomised trial. M Nicolson D Gilligan I Smith H Groen C Manegold J van Meerbeeck P Hopwood M Nankivell C Pugh RJ Stephens, et al. J Clin Oncol (Meeting Abstracts) 2007 25 18-suppl 7518
2. A phase III randomized study of surgery alone or surgery plus preoperative gemcitabine-cisplatin in early-stage non-small cell lung cancer (NSCLC): Follow-up data of Ch.E.S. GV Scagliotti U Pastorino JF Vansteenkiste L Spaggiari F Facciolo T Orlowski A Maiorino M Hetzel C Visseren-Grul V Torri, J Clin Oncol (Meeting Abstracts) 2008 26 15-suppl 7508
3. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. JP Pignon H Tribodet GV Scagliotti JY Douillard FA Shepherd RJ Stephens A Dunant V Torri R Rosell L Seymour, et al. J Clin Oncol 2008 26 21 3552 3559 10.1200/JCO.2007.13.9030 18506026
4. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: Systematic review and indirect comparison meta-analysis of randomized trials. E Lim G Harris A Patel I Adachi L Edmonds F Song, J Clin Oncol (Meeting Abstracts) 2008 26 15-suppl 7546
5. Surgery (S) alone, preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy followed by S, or S followed by adjuvant (adj) PC chemotherapy in early-stage non-small cell lung cancer (NSCLC): Results of the NATCH multicenter, randomized phase III trial. E Felip B Massuti G Alonso JL Gonzlez-Larriba C Camps D Isla E Costas JJ Snchez F Griesinger R Rosell, J Clin Oncol (Meeting Abstracts) 2009 27 15S 7500
6. Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non-Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. GM Strauss JE Herndon II MA Maddaus DW Johnstone EA Johnson DH Harpole HH Gillenwater DM Watson DJ Sugarbaker RL Schilsky, et al. J Clin Oncol 2008 26 31 5043 5051 10.1200/JCO.2008.16.4855 18809614
7. S9900: Surgery alone or surgery plus induction (ind) paclitaxel/ carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Follow-up on a phase III trial. K Pisters E Vallieres PA Bunn Jr J Crowley K Chansky R Ginsberg DR Gandara Southwest Oncology G, J Clin Oncol (Meeting Abstracts) 2007 25 18-suppl 7520
8. Updated survival analysis of JBR.10: A randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC). MD Vincent C Butts L Seymour K Ding B Graham P Twumasi-Ankrah D Gandara J Schiller M Green F Shepherd, J Clin Oncol (Meeting Abstracts) 2009 27 15S 7501
9. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. R Arriagada A Dunant JP Pignon B Bergman M Chabowski D Grunenwald M Kozlowski C Le Pechoux R Pirker MI Pinel, et al. J Clin Oncol 28 1 35 42 10.1200/JCO.2009.23. 2272 19933916
10. Duration of first-line chemotherapy in advanced non small-cell lung cancer: less is more in the era of effective subsequent therapies. MA Socinski TE Stinchcombe, J Clin Oncol 2007 25 33 5155 5157 10.1200/JCO.2007.13.4015 18024862
11. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. F Grossi M Aita A Follador C Defferrari A Brianti G Sinaccio O Belvedere, Oncologist 2007 12 4 451 464 10.1634/theoncologist.12-4-451 17470688
12. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC). CP Belani T Brodowicz T Ciuleanu JH Kim M Krzakowski E Laack YL Wu P Peterson K Krejcy C Zielinski, J Clin Oncol (Meeting Abstracts) 2009 27 18S RA8000
13. Epidermal growth factor receptor family in lung cancer and premalignancy. WA Franklin R Veve FR Hirsch BA Helfrich PA Bunn Jr, Semin Oncol 2002 29 1 Suppl 4 3 14 10.1053/sonc.2002.31520 11894009
14. Erlotinib in Previously Treated Non-Small-Cell Lung Cancer. FA Shepherd J Rodrigues Pereira T Ciuleanu EH Tan V Hirsh S Thongprasert D Campos S Maoleekoonpiroj M Smylie R Martins, et al. N Engl J Med 2005 353 2 123 132 10.1056/NEJMoa050753 16014882
15. TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non-Small-Cell Lung Cancer. RS Herbst D Prager R Hermann L Fehrenbacher BE Johnson A Sandler MG Kris HT Tran P Klein X Li, et al. J Clin Oncol 2005 23 25 5892 5899 10.1200/JCO.2005.02.840 16043829
16. Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non-Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial. U Gatzemeier A Pluzanska A Szczesna E Kaukel J Roubec F De Rosa J Milanowski H Karnicka-Mlodkowski M Pesek P Serwatowski, et al. J Clin Oncol 2007 25 12 1545 1552 10.1200/JCO.2005.05.1474 17442998
17. SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. F Cappuzzo T Ciuleanu L Stelmakh S Cicenas A Szczesna E Juhasz E Esteban Gonzalez O Molinier G Klingelschmitt G Giaccone, et al. J Clin Oncol (Meeting Abstracts) 2009 27 15S 8001
18. Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC. W Brugger N Triller M Blasinska-Morawiec S Curescu R Sakalauskas G Manikhas J Mazieres R Whittom K Rohr F Cappuzzo, et al. J Clin Oncol (Meeting Abstracts) 2009 27 15S 8020
19. FAST-ACT: A phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). JS Lee J Ignacio C Yu C Zhou Y Wu Y Chen L Zhang K Jin M Johnston TS Mok, J Clin Oncol (Meeting Abstracts) 2008 26 15-suppl 8031
20. Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer. A Sandler R Gray MC Perry J Brahmer JH Schiller A Dowlati R Lilenbaum DH Johnson, N Engl J Med 2006 355 24 2542 2550 10.1056/NEJMoa061884 17167137 (Pubitemid 44917502)
21. Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non Small-Cell Lung Cancer. RS Herbst VJ O'Neill L Fehrenbacher CP Belani PD Bonomi L Hart O Melnyk D Ramies M Lin A Sandler, J Clin Oncol 2007 25 30 4743 4750 10.1200/JCO.2007.12.3026 17909199
22. A phase III, multicenter, placebo-controlled, double-blind, randomized, clinical trial to evaluate the efficacy of bevacizumab in combination with erlotinib compared with erlotinib alone for treatment of advanced non-small cell lung cancer after failure of standard first line chemotherapy (BETA). J Hainsworth R Herbst, Journal of Thoracic Oncology 2008 3 11 302
23. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). VA Miller P O'Connor C Soh F Kabbinavar for the AI, J Clin Oncol (Meeting Abstracts) 2009 27 15S BA8002
24. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study. KJ O'Byrne I Bondarenko C Barrios C Eschbach U Martens Y Hotko C Kortsik I Celik C Stroh R Pirker, J Clin Oncol (Meeting Abstracts) 2009 27 15S 8007
25. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. R Pirker JR Pereira A Szczesna J von Pawel M Krzakowski R Ramlau I Vynnychenko K Park CT Yu V Ganul, et al. Lancet 2009 373 9674 1525 1531 10.1016/S0140-6736(09)60569-9 19410716
26. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. FR Hirsch RS Herbst C Olsen K Chansky J Crowley K Kelly WA Franklin PA Bunn Jr M Varella-Garcia DR Gandara, J Clin Oncol 2008 26 20 3351 3357 10.1200/JCO.2007.14.0111 18612151
27. K-RAS mutations and EGFR-related markers as potential predictors of the cetuximab benefit in 1st line advanced non-small cell lung cancer: results from the BMS099 study. S vKhambata-Ford CT Harbison LL Hart M Award L Xu, et al. Journal of Thoracic Oncology 2008 3 11 304
28. S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study. D Gandara ES Kim RS Herbst J Moon MW Redman SR Dakhil F Hirsch PC Mack W Franklin K Kelly, J Clin Oncol (Meeting Abstracts) 2009 27 15S 8015
29. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. ES Kim V Hirsh T Mok MA Socinski R Gervais YL Wu LY Li CL Watkins MV Sellers ES Lowe, et al. Lancet 2008 372 9652 1809 1818 10.1016/S0140-6736(08)61758-4 19027483
30. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. K Park K Goto, Curr Med Res Opin 2006 22 3 561 573 10.1185/030079906X89847 16574039
31. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. JG Paez PA Janne JC Lee S Tracy H Greulich S Gabriel P Herman FJ Kaye N Lindeman TJ Boggon, et al. Science 2004 304 5676 1497 1500 10.1126/science.1099314 15118125
32. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). L Paz-Ares JM Sanchez A Garcia-Velasco B Massuti G Lopez-Vivanco M Provencio A Montes D Isla ML Amador R Rosell, et al. J Clin Oncol (Meeting Abstracts) 2006 24 18-suppl 7020
33. Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. TS Mok YL Wu S Thongprasert CH Yang DT Chu N Saijo P Sunpaweravong B Han B Margono Y Ichinose, et al. N Engl J Med 2009 361 10 947 957 10.1056/NEJMoa0810699 19692680
34. Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). M Fukuoka Y Wu S Thongprasert C Yang D Chu N Saijo C Watkins E Duffield A Armour T Mok, J Clin Oncol (Meeting Abstracts) 2009 27 15S 8006
35. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. RS Herbst JV Heymach MS O'Reilly A Onn AJ Ryan, Expert Opin Investig Drugs 2007 16 2 239 249 10.1517/13543784.16.2.239 17243944
36. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. SN Holden SG Eckhardt R Basser R de Boer D Rischin M Green MA Rosenthal C Wheeler A Barge HI Hurwitz, Ann Oncol 2005 16 8 1391 1397 10.1093/annonc/mdi247 15905307
37. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. JV Heymach BE Johnson D Prager E Csada J Roubec M Pesek I Spasova CP Belani I Bodrogi S Gadgeel, et al. J Clin Oncol 2007 25 27 4270 4277 10.1200/JCO.2006.10.5122 17878479
38. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC). RS Herbst Y Sun S Korfee P Germonpre N Saijo C Zhou J Wang P Langmuir SJ Kennedy BE Johnson, J Clin Oncol (Meeting Abstracts) 2009 27 15S RA8003
39. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL). R De Boer O Arrieta M Gottfried FH Blackhall J Raats CH Yang P Langmuir T Milenkova J Read J Vansteenkiste, J Clin Oncol (Meeting Abstracts) 2009 27 15S 8010
40. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST). RB Natale S Thongprasert FA Greco M Thomas CM Tsai P Sunpaweravong D Ferry P Langmuir JA Rowbottom GD Goss, J Clin Oncol (Meeting Abstracts) 2009 27 15S 8009
41. Anticancer activities of histone deacetylase inhibitors. JE Bolden MJ Peart RW Johnstone, Nat Rev Drug Discov 2006 5 9 769 784 10.1038/nrd2133 16955068
42. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. AM Traynor S Dubey JC Eickhoff JM Kolesar K Schell MS Huie DL Groteluschen SM Marcotte CM Hallahan HR Weeks, et al. J Thorac Oncol 2009 4 4 522 526 10.1097/JTO.0b013e3181952478 19347984
43. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. SS Ramalingam RA Parise RK Ramanathan TF Lagattuta LA Musguire RG Stoller DM Potter AE Argiris JA Zwiebel MJ Egorin, et al. Clin Cancer Res 2007 13 12 3605 3610 10.1158/1078-0432.CCR-07-0162 17510206
44. Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of advanced non-small cell lung cancer (NCI 7863). SS Ramalingam M Maitland P Frankel AE Argiris M Koczywas B Gitlitz I Espinoza-Delgado EE Vokes DR Gandara CP Belani, J Clin Oncol (Meeting Abstracts) 2009 27 15S 8004